TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease
暂无分享,去创建一个
K. Yoo | Jong Hoon Park | E. Jho | Sumin Oh | S. Nam | Yong Kyun Kim | Eunjeong Seo | Min-Ha Park | J. Kim | Jong Young Lee | E. Lee | Jaehee Jun
[1] A. Boletta,et al. Polycystin-1 Regulates Actomyosin Contraction and the Cellular Response to Extracellular Stiffness , 2019, Scientific Reports.
[2] C. Murphy,et al. YAP and TAZ are distinct effectors of corneal myofibroblast transformation , 2019, Experimental eye research.
[3] D. Lim,et al. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis , 2019, Circulation research.
[4] C. O’Brien,et al. The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation. , 2018, Bone.
[5] D. Hwang,et al. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. , 2018, Cancer research.
[6] F. Qian,et al. A RhoA–YAP–c-Myc signaling axis promotes the development of polycystic kidney disease , 2018, Genes & development.
[7] B. Ren,et al. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell , 2018, The Journal of Biological Chemistry.
[8] C. Mei,et al. Scribble influences cyst formation in autosomal‐dominant polycystic kidney disease by regulating Hippo signaling pathway , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] C. Liang,et al. Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. , 2018, JCI insight.
[10] Fachao Zhi,et al. YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury , 2018, Cell Death & Disease.
[11] Jeremy C. Smith,et al. Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis , 2018, The Journal of clinical investigation.
[12] U. Apte,et al. Increased YAP Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF. , 2017, Gene expression.
[13] Bo Hye Kim,et al. Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models , 2017, Scientific Reports.
[14] D. Matallanas,et al. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function , 2017, Stem Cells.
[15] Soohong Min,et al. The Hippo-Salvador signaling pathway regulates renal tubulointerstitial fibrosis , 2016, Scientific Reports.
[16] R. Salomon,et al. Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through YAP Dysregulation , 2016, PLoS genetics.
[17] M. Sudol,et al. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells* , 2015, The Journal of Biological Chemistry.
[18] K. Guan,et al. YAP and TAZ: a nexus for Hippo signaling and beyond. , 2015, Trends in cell biology.
[19] D. Nguyen,et al. Neuregulin 1–activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration , 2014, Science Signaling.
[20] Giuseppe Basso,et al. YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.
[21] Xaralabos Varelas,et al. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.
[22] E. Olson,et al. Hippo pathway effector Yap promotes cardiac regeneration , 2013, Proceedings of the National Academy of Sciences.
[23] Cristian Coarfa,et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. , 2013, Cell reports.
[24] T. Pawson,et al. Yap- and Cdc42-Dependent Nephrogenesis and Morphogenesis during Mouse Kidney Development , 2013, PLoS genetics.
[25] K. Guan,et al. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.
[26] C. Edelstein,et al. Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside , 2012, Kidney research and clinical practice.
[27] M. Breuning,et al. Altered Hippo signalling in polycystic kidney disease , 2011, The Journal of pathology.
[28] Randy L. Johnson,et al. Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.
[29] V. Patel. Balancing the Wnts in polycystic kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.
[30] Frederic A. Fellouse,et al. The Hippo pathway regulates Wnt/beta-catenin signaling. , 2010, Developmental cell.
[31] Madeline A. Lancaster,et al. Impaired Wnt–β-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy , 2009, Nature Medicine.
[32] V. Torres,et al. Polycystic kidney disease. , 2009, Annual review of medicine.
[33] Lawrence Lum,et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.
[34] L. Cantley,et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. , 2008, Human molecular genetics.
[35] H. Aburatani,et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. , 2008, American journal of physiology. Renal physiology.
[36] Y. Shaul,et al. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 , 2007, Cell Death and Differentiation.
[37] H. Ko,et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1 , 2007, Proceedings of the National Academy of Sciences.
[38] Y. Uchijima,et al. Transcriptional activity of Pax3 is co-activated by TAZ. , 2006, Biochemical and biophysical research communications.
[39] E. Olson,et al. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] Thomas Benjamin,et al. TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation , 2005, Science.
[42] Albert C M Ong,et al. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. , 2005, Kidney international.
[43] M. Yaffe,et al. TAZ Interacts with TTF-1 and Regulates Expression of Surfactant Protein-C* , 2004, Journal of Biological Chemistry.
[44] A. Kahn,et al. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the β-catenin gene , 2001, Oncogene.
[45] V. D’Agati,et al. C-myc as an inducer of polycystic kidney disease in transgenic mice. , 1991, Kidney international.
[46] J. García Rodríguez,et al. [Polycystic Kidney Disease]. , 2005, Actas urologicas espanolas.